Abstract 62P
Background
According to the GLOBOCAN database 2020, colorectal cancer (CRC) has the fourth-highest incidence in Indonesia. In Yogyakarta province, CRC is the third most prevalent cancer. CRC usually present with common gastrointestinal complaints. The relationship between the chief complaint and clinicopathology parameters has been rarely explored in Indonesia. We, therefore, aimed to analyze their association with our CRC patients.
Methods
A retrospective study was done on 1,276 CRC cases diagnosed between January 2016 and December 2019 at Dr. Sardjito Hospital, Yogyakarta. We collected secondary data from the CRC clinical registry database, including demography, chief complaints and clinicopathology features. Data on hospitals where CRC diagnostic procedure was performed based on biopsy or resection. Chi-square analysis was used to determine the relationship between the chief complaint and clinicopathology parameters.
Results
The most common chief complaints were hematochezia (34.4.%), bloating (24.8%), constipation (23%), diarrhea (17.5%), weight loss (12.1%) and abdominal mass (9.8%). Hematochezia was associated with tumor site, T status, N status, M status, clinical stage, performance status, and type of diagnostic hospital. Diarrhea was associated with age, hemoglobin, serum albumin, and type of diagnostic hospital. Constipation was associated with gender, tumor site, N status, serum albumin, and type of diagnostic hospital. Bloating was associated with tumor site, M status, clinical stage, histological grade, serum albumin, performance status, and type of diagnostic hospital. Weight loss was related to the tumor site, M status and diagnostic hospital. Abdominal mass was associated with age, gender, and serum albumin. All p values were < 0.05.
Conclusions
The chief complaints of CRC were associated with various clinicopathological parameters that may influence the patient's prognosis. Because complaints associated with CRC are similar to other gastrointestinal diseases, the awareness of clinicians to immediately follow up is needed so that patients can be identified at an earlier stage. Referral process across hospitals may also serve as a target for health system improvement.
Clinical trial identification
Editorial acknowledgement
The authors thank Yana Suryani, Rosita Yunanda Purwanto, and Nugira Dinantia for technical assistance and coordination.
Legal entity responsible for the study
Yasjudan Rastrama Putra.
Funding
The authors received financial support from the Applied Research Grant 2020–2021, The Indonesian Ministry of Research, Technology, and Higher Education and the Institutional Links grant, ID 527558574, under the Newton Institutional Link-Indonesia KLN Fund partnership, funded by the UK Department for Business, Energy and Industrial Strategy and Indonesia Ministry of Research Technology & Higher Education and delivered by the British Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
130P - Radiation induced lymphopenia (RAILs on time saves nine): In carcinoma esophagus
Presenter: Sheel Mohanty
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02